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Chapter 1 
Introduction 
 
 
 
Facio-scapulo-humeral muscular dystrophy (FSHD; OMIM #158900) is a fascinating and 
enigmatic genetic disease. It displays an autosomal dominant inheritance and is the third 
most common inherited muscular dystrophy after dystrophinopaties and myotonic 
dystrophy, with a prevalence of at least 1 in 20.000 (Padberg, 1982). 
 
1.1 Historical aspects. The earliest recognizable descriptions of FSHD  were made in the 
second half of the 19th century. Up to the middle of 1800s, most physicians held the 
opinion that chronic muscular atrophy was caused by anterior horn cell disease, causing 
what we would nowadays recognize as spinal muscular atrophy (SMA). The observation of 
hypertrophy of some muscles in patients with atrophy of other muscles was such an 
intriguing finding that it drew the attention of many clinicians. In a series of articles in the 
“Archives of Générales de Médicine” of 1868, Guillaime Duchenne de 
Boulogne published his “Recherches sur la paralysie musculaire 
pseudo-hypertrophyque ou paralysie myo-sclérosique”, describing the 
condition that now bears his name. In 1852 Cruveilheirs described 
extreme atrophy of the anterior spinal cord in an adult with proximal 
weakness, and later facial and lingual involvement. Duchenne quoted 
this case in recognition of the fact that facial and lingual involvement 
occurred late in the neurogenic atrophies. However, as noted by 
Padberg (1982), he failed to comment on a second patient described 
by Cruveilheirs, a 18-years old man with a severe FSH syndrome who 
had died in 1848 of variola and on whom autopsy showed the brain, 
spinal cord and the peripheral nerves to be unaffected. This man had 
a severe facio-scapulo-humeral syndrome but complete sparing of the 
central, spinal and peripheral nervous system. This patient almost 
certainly represents the first description of FSHD in medical literature.  
While Duchenne was concentrating on pseudohypertrophy, in 1884
Vulpian  presented a summary of Landouzy and Dejerine’s observatio
atrophique progressive, myopathie hereditaire debutant dans l’enfan
alteration du systeme nerveux” at a meeting of the “Académie des S
17th.  Fig. 1 Landouzy and Dejerine hort alleles (<20kb) 
ns “de la myopathie 
ce par la face, sans 
ciences” on January 
One  year  later (1885a, 1885b), Landouzy  and  Dejerine (Fig.1) published their   first   
article  in   the   “Revue   de   Médicine”  about   “La myopathie atrophique progressive;  
myopathie san  neuropathie  debutant  d’ordinaire  dans  l’enfance,  par  la face”, in which 
they described an autopsy performed on a man who died of tubercolosis when he was 24 
years old. At the age of three, atrophy of the facial muscles was noted and this was his only 
symptom. As they observed: “from the age of eighteen little by little the atrophy reached the 
upper limbs, then all the other muscles of the body”. During the subsequent years the 
atrophy slowly progressed to involve the muscles of the trunk and pelvic girdle. There was 
no sensory abnormalities and the tendon reflexes were absent. He never had experienced 
any muscle pains. 
Landouzy and Dejerine stressed the clinical and histological integrity of the muscles of the 
tongue, pharynx and larynx and also of the masseter, the temporal and the pterygoid 
muscles. The extraocular muscles and the levator 
palpebrae muscles were unaffected as well. At post-
mortem examination the authors found no 
abnormalities on brain, spinal cord, peripheral 
nerves and intramuscular nerve endings. 
They noted the hereditary nature of FSHD since the 
father, brother and sisters of the proband were 
affected. The pedigree (Fig.2) showed a definite 
autosomal dominant pattern of inheritance. 
It is interesting to see that the disease seemingly 
skipped the second generation. Of course it is quite 
possible that the woman II,1 in the second Fig. 2 Family L 4 Clinical characterization of facio-scapulo-humeral muscular dystrophy (FSHD) with short alleles (<20kb) 
 
generation might have represented an abortive case. Furthermore, if someone realizes that 
the father of the proband developed muscle atrophy in the shoulder girdle at the age of 26 
and noted facial involvement when he was 32 years old, all the potential pitfalls involved in 
the diagnosis of the FSHD are already obvious from the first published pedigree. 
The proband fitted the description of Duchenne’s “infantile form of progressive fatty 
muscular atrophy”. Landouzy and Dejerine assumed that Duchenne’s and their own 
descriptions were about the same disease and that they had proven its myopathic nature. 
The proband’s father and similar familial and sporadic cases described in subsequent 
articles, led Landouzy and Dejerine to improve the diagnostic criteria of the disorder that 
they had named “facioscapulohumeral type of progressive myopathy”. The age of onset 
was said not necessarily to be in infancy. Furthermore, they stressed that the disease did 
not always start with involvement of the facial muscles. In such cases shoulder girdle 
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weakness was the starting symptom; some patients never developed facial weakness. 
Landouzy and Dejerine described the autopsy of  a case  that had  lacked clinical 
involvement of the facial muscles,  but showed microscopical abnormalities, suggesting a 
myopathy on examination of these muscles.  
Although the concept of a primary muscle disease as a cause of a slowly progressive 
muscular atrophy was finally accepted by the end of the nineteenth century, the discussion 
regarding the classification of the human myopathies had only just begun. The introduction 
of genetical criteria proved to be very useful. 
Weitz (1921) was the first to recognize the possibility of autosomal dominant, autosomal 
recessive and X-linked recessive modes of inheritance of the myopathies. Davidenkow 
(1930) studied 554 cases of what he called “dystrophia musculorum progressiva”; most of 
the cases were collected from literature. He was the first to recognize abortive cases of 
FSHD and he also drew attention to the fact that some affected members of families with 
FSHD failed to demonstrate facial weakness.  
Julia Bell (1942, 1943) studied 1228 cases of muscular dystrophy from literature and 113 
records from the National Hospital, Queen Square, London and concluded that all three 
modes of inheritance seemed to occur. She divided the clinical data into three groups 
based on two criteria, pseudohypertrophy and facial involvement, hoping to find a certain 
pattern of inheritance for each group. Her first group consisted of all cases exhibiting 
pseudohypertrophy of muscles, but cases with facial involvement were excluded. The 
second group contained all cases that had unaffected facial muscles and no 
pseudohypertrophy. The third group included all cases with weakness of the facial muscles 
with or without hypertrophy of muscles. Bell could not ascribe a single pattern of 
inheritance to each group, perhaps due to ease with which she accepted the diagnosis of 
reported cases as definitely established and to the fact that in many instances the families 
were not completely examined, as Tyler (1950) argued. This argument is of particular 
relevance with respect to FSHD, as all Bell’s 337 cases of group 3 were collected from the 
literature, because, in the 14-years period covered by the study, no such cases were seen 
in the National Hospital. 
Pseudohypertrophy and facial involvement continued to be decisive criteria in other 
attempts at classification of the muscular dystrophies, because the age of onset was 
considered too difficult to established in many cases. Levison (1951) started from clinical 
criteria and concluded from eight families that the FSH type of muscular dystrophy had an 
autosomal dominant mode of inheritance. He stressed that he had not seen patients with 
marked atrophy or paresis of the orbicularis oculi muscles as described by Landouzy and 
Dejerine. He also distinguished a scapulohumeral type of muscular dystrophy that was 
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sporadic in five families and present in two brothers of another family. Finally, he discerned 
an intermediate type between the FSH and scapulohumeral type in which the facial 
muscles were only slightly involved. The six cases of this type were all sporadic ones. 
However, it is not stated how extensively the families were examined. 
Stevenson (1953) thought an autosomal recessive mode of inheritance to be present in his 
families with facial involvement and included these families in his group of “autosomal 
recessive limb-girdle muscular dystrophy”, as he judged weakness of the facial muscles an 
insufficient criterion for separation into two different diseases. Stevenson’s examination of 
the families is certainly open for criticism. His view did not harmonize with the experience of 
many clinicians who had become accustomed to find an autosomal dominant mode of 
inheritance in most families with muscular dystrophy and involvement of the facial muscles. 
Therefore, Walton and Nattrass (1954) encountered little objection when they defined the 
pattern on inheritance of FSHD being usually autosomal dominant and only occasionally 
autosomal recessive. These authors were impressed by the occurrence of abortive cases 
that can obscure the true pattern of inheritance in many families. They stressed that “the 
question of minor facial involvement is of the greatest importance and may well be a 
reason for confusion in published work since many cases which were truly FSH may have 
been classified as scapulohumeral”. 
The classification of the muscular dystrophies given by Walton and Nattrass has proven to 
be very successful and formed the basis of all other attempts all classification thereafter. It 
ended several decades of confusion about FSHD. 
 
1.2 Clinical features. Clinical features of FSHD  are  mainly three: early involvement of the 
face; subsequent involvement of the upper limb girdle before the lower; and at-times 
striking asymmetry of muscle involvement. 
 
Facial involvement. Facial muscles hyposteny is, generally, the earliest sign of disease and 
gives the patient a particular myopathic face.  
From the very first descriptions by Landouzy (1874) and Landouzy and Dejerine (1885), it 
was clear that FSHD was a “progressive muscular atrophy that starts in childhood with the 
face” producing a “facies particulier”, which was apparent from 3 years of age in their 
patient. As Walton and Nattrass (1954) point out, however, as many as 2/3 of patients are 
completely unaware of facial weakness.  
FSHD is not the only condition to affect the face, but Landouzy and Dejerine were the first 
to use the term “myopathic facies”. In myotonic dystrophy the distribution of involved 
muscles is quite different (Harper, 2001). In other myopathies, facial involvement is usually 
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a later feature and often, less severe (Walton and Nattrass, 1954; Ricker and Mertens, 
1968; van der Kooi et al., 1996). 
Orbicularis oculi involvement often prevents the complete closure of the eyelids. The 
extrinsic muscles of the eyes is almost never involved. The most striking feature is an 
aspect of hyperthyroid  without pro-ptosis,  the  limbo of  the  eye is  often visible,  
especially in the lower eyelid. In milder cases the blinking is often abnormal and the patient 
tends to rotate upward when the eye blinks (Bell's phenomenon). In rare cases more 
severe weakness may lead to an exposure keratitis and corneal scarring (Padberg et al, 
1995), but this can usually be prevented by appropriate intervention, including surgical 
insertion of gold weights and lateral tarsorrhaphy (Sansone et al, 1997). 
Whistling or puffing cheeks, drinking from a straw acts become almost impossible because 
of  orbicular oris muscles and zygomatic muscles involvement; the smile is flat and 
transverse to the deficit of the laugh muscles and savings of the platysma muscle, lips have 
a particular tendency to protrude and flaccidity. The lower lip tends to be the more 
prominent and both together somewhat protuberant described by some as “bouche de 
tapir” (Padberg, 1982; Brooke, 1986). 
The temporalis and masseter muscles, in contrast to myotonic dystrophy, are usually 
spared. 
Like the limbs, asymmetric facial involvement is not unusual, being most evident on 
smiling. 
Most clinicians recognize that not all patients will develop facial weakness, and the 
diagnostic criteria produced following a European Neuromuscular Centre workshop allow 
50% of individuals within a family not to have facial involvement (Padberg, 1992). 
 
Upper limb involvement. More than 80% of all patients notice shoulder girdle weakness as 
the first symptom of the disease, when they blame a 
difficulty abducting the arms.  
The chief muscles involved are latissimus dorsi, serratus 
anterior, pectoralis, subscapularis, rhomboids, trapezius, 
supraspinatus and infraspinatus and deltoid.  
The weakness of the muscles of the scapula fixators 
(serratus anterior, lower trapezius muscle, rhomboid 
muscles) prevents the complete lifting of the arms and 
promotes the appearance of scapular winging (Fig.3). The u
be spared until very late in the course of the disease
movement of the winged scapula. Anteriorly, the clavicularFig. 3 Scapular winging  (FSHD) with short alleles (<20kb) 
pper fibres of trapezius tend to 
, contributing to the superior 
 head of the pectoralis major is 
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one of the first muscles to be involved producing a localized atrophy and additional typical 
axillary fold pointing towards the manubrium sterni. Involvement of the deltoid muscle is 
also characteristically localize to the proximal fibres, producing at-times strikingly visible 
shelf where the distal muscle is relatively spared. 
In later stages, the dystrophic process extends to the biceps and triceps brachii muscles, 
with relative sparing of the muscles of the forearm.  
 
Lower limb involvement. Classical  forms of  FSHD can be completed  with the appearance 
of weakness of the muscles of peroneal compartment and the onset of foot drop (Padberg, 
1982). 
Subsequently, the weakness tends to spread to the muscles of the pelvic girdle, which 
contributes, in association with deficiency of abdominal muscles, the appearance of the 
lumbar lordosis.  
The appearance of foot drop may occur earlier in the disease and early involvement of the 
pelvic girdle is quite rare. 
To return to the more typical presentation, following involvement of the shoulder girdle, 
there are two common modes of progression. In both, weakness is likely to spread 
simultaneously down the arm to involve the biceps, triceps and brachioradialis. At about the 
same stage, in the lower limb, a little more commonly, involvement of the pelvic girdle is 
first noted (Becker, 1953; Walton and Nattrass, 1954; Chung and Morton, 1959). Also fairly 
commonly, the pelvis may be spared and the weakness may “jump” or “skip” to involve the 
peroneal muscles first (Tyler and Stephens, 1950; Chyatte et al, 1966; Kazakov et al, 1974; 
Padberg, 1982). It is an important diagnostic feature that involvement of the upper limb 
girdle is virtually always earlier and more severe than the lower limb girdle. 
 
Abdominal muscles. In many cases, an upward movement of the umbilicus to the simple 
bending of the neck (Beevor's sign), due to deficiency of the abdominal rectus muscles, 
allows us to highlight the involvement of the abdominal muscles (Awerbuch et al, 1990). 
 
Extramuscular involvement. The most common extramuscular manifestations of FSHD is 
probably hearing loss, which occurs in about 75% of the patients. Hearing impairment has 
been reported to be the presenting symptom of FSHD in some families. (Taylor  et al, 
1982).   
FSHD is, moreover, associated with retinal telangiectasias, a blood vessel disorder of the 
retina, in 60% of cases (Tawil and Van Der Maarel, 2006). Coats’ disease, a severe 
exudative vascular retinopathy, has been described by a number of authors in association 
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with FSHD. According to Manschot and de Bruijn (1967), Coats re-defined this disease in 
his second German paper as a condition which is usually unilateral, non-hereditary, with an 
exudative vascular retinopathy consequent upon an underlying telangiectasias of small 
retinal blood vessels. It usually affects juvenile or infant males “in the absence of systemic 
disease” (Coats, 1912). It is often associated with massive retinal exudates, consequential 
retinal detachment and blindness. 
The first description of an association with FSHD is generally accepted to be that of Small 
in 1968 (Small, 1968). The clinical cases presented by Small as “muscular dystrophy” are 
certainly convincing as cases of childhood-onset FSHD. For the next 25-30 years, over 55 
cases of severe infantile FSHD were described, many with retinal vasculopathy (reviewed 
by Brouwer et al, 1991; Fitzsimons et al, 1987).  
In spite of myotonic dystrophy, Emery-Dreifuss muscular dystrophy (EDMD) or Xp21 
dystrophies or Limb Girdle Muscular Dystrophy type 1 (LGMD1), mild cardiac abnormalities 
were observed only in 5% of FSHD population (Laforêt et al, 1998). Tyler and Stephens 
(1950) in their large Utah FSHD family noted a high prevalence of cardiac disease. The 
prevalence of rheumatic fever was high in Utah anyway but the prevalence of “signs 
suggestive of rheumatic disease” was 12 times higher at 87 per 1000 members of the 
family. Other early studies were hampered by the probable inclusion of other disparate 
diagnoses now known to be associated with cardiac disease such an EDMD and scapulo-
peroneal muscular dystrophy with cardiomyopathy.  
Manning and Cropp (1958) compared standard 12-lead electrocardiograms of 28 cases of 
juvenile muscular dystrophy with 10 patients who had adult onset muscular dystrophy or 
FSHD. They found that more than 70% of the juvenile group had abnormal ECGs but in 
spite of the inclusion of other diagnoses still found “little or nothing abnormal” in the FSHD 
group. Clinical description suggests that only two of these cases fitted as FSHD phenotype. 
Of these, one exhibited ECG changes compatible with an incomplete right bundle bunch 
block (RBBB). 
Stevenson et al (1990)  attempted to find  evidence of atrial standstill in FSHD.  On 
standard 12-lead ECG, they found minor p wave abnormalities in 60% (18/30) of patients. 
Twelve patients underwent  intracardiac electrophysiological studies with direct stimulation 
of the atria inducing arrhytmias in 80% of patients compared to 17% of controls. Three 
patients had mild prolongation of the PR interval, two patients exhibited right bundle bunch 
block and one left anterior hemiblock.  The authors concluded that in patients with FSHD 
the heart was unusually sensitive to inducible arrhythmias but they were unclear about the 
clinical significance of this findings.  
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The Dutch group of de Visser et al.  (1992) compared Becker and FSHDs with Bethlem 
Myopathy, performing standard ECG, M-Mode and two-dimensional ecocardiography, and, 
in the cases of FSHD, also 24-hours Holter-monitoring. Apart from one patient with mitral 
valve  prolapse, cardiac changes were absent  in the remaining 27 FSHD patients. 
Thallium-201 single-photon-emission computed tomography (T1-201-SPECT), in 
conjunction with a pharmacologically induced (dobutamine) stress test, was used to 
evaluate 15 members of a family with molecularly confirmed FSHD  (Faustmann et al, 
1996). Only the affected members of the family showed a reduced thallium-201 uptake 
reflecting, in the author’s opinion, cardiomyogenic changes related to FSHD. Following 
these two studies, Laforêt et al. (1998) assessed 100 FSHD patients from 90 families with 
molecularly confirmed FSHD . Surface ECG showed no abnormality in 53% of patients. 
Minor abnormalities were seen in  38 patients  including RBBB, sinus bradycardia, short 
PR interval, repetitive supraventricular extrasystoles and others. Conduction abnormalities 
were induced by intracardiac stimulation in two patients; two other patients had 
symptomatic cardiac disease, one with symptomatic bradycardia and the other with 
nocturnal atrial dysrhythmias. A fifth patient had a right ventricular cardiomyopathy and 
related ventricular tachycardia. There was no correlation between severity of FSHD, age of 
onset or size of double-digest fragment. In absence of other cardiovascular risk factors the 
authors concluded that 5% of their patients exhibited FSHD-related cardiac disease. More 
recent studies suggest that although symptomatic cardiac disease is still rare in FSHD, 
possibly 5% of patients show clear evidence of cardiac abnormality. Most of these appear 
to be rhythm disturbances. 
Pulmonary dysfunction is not a well-recognized feature of FSHD. Even in severely affected 
patients, respiratory involvement is rare. It can occur in extremely severe cases and this 
may be secondary to skeletal complications (more likely do to rare cases of scoliosis rather 
than the commoner hyperlordosis). In other cases, especially in infantile-onset FSHD with 
very short p13-E11  fragments,  presumed primary diaphragmatic  and/or intercostal 
muscle involvement may very rarely cause respiratory failure (Nakagawa et al, 1996 and 
1997). 
In 1988 Yasukohci et al described two sibling cases of FSHD. One was characterized by 
sensorineural hearing loss, marked tortuosity of retinal arterioles, an early onset and 
progression of severe restrictive-type pulmonary dysfunction, and cor pulmonale. The other 
had a mild course of FSHD without involvement of any other organ than muscles at the 
time of diagnosis.  
In a recent study sixteen patients with moderately advanced FSHD and 16 healthy controls 
were evaluated to establish the prevalence and type of pulmonary and respiratory muscle 
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dysfunction in FSHD. Lung function tests showed an increased residual volume in five 
patients. There was a significant difference in global respiratory muscle function in patients 
versus controls; weakness was mild, and it affected expiratory more than inspiratory 
muscles. There was no significant difference in the diaphragm inspiratory action of patients 
versus controls. The dystrophic process that underlies FSHD did not significantly involve 
the muscles of the diaphragm, but it caused mild global respiratory muscle weakness that 
affected expiratory more than inspiratory muscles. (Stübgen et al, 2009). 
 
Clinical variability and progression. There is a wide variability in the spectrum of disease 
among patients, ranging from subjects with very mild muscle weakness, who are almost 
unaware of being affected, to those who are wheelchair-dependent. This great variability in 
clinical expression is present even within the same family and its explanation remains an 
open question. A mild gender effect has been noted by several authors; women tend to be 
more often asymptomatic, have a slightly later onset and a somewhat milder course of the 
disease (Tawil et al, 2006).  
Natural history studies show a rate of progression that is generally slow and steady (The 
FSH-Dy study, 1997; Stubgen et al, 2010). So far progression of FSHD has been described 
as if it were inevitable that all FSHD patients go on to develop a relentless progressive 
dystrophy involving all muscles of the limbs. However, many patients appear to have long 
static phases, where progression is so slow that they appear to be in a plateau phase. Most 
authors would agree that FSHD does not have true plateau phases, but rather that 
progression in some patients decelerates to such an extent that is appears to almost stop.  
For many patients there is, therefore, no further apparent progression, and in 30% remain 
only mildly affected throughout life (Lunt and Harper, 1991). Thus in mild cases, there may 
only be very slight facial weakness, only noted by an inability to whistle, and mild weakness 
of shoulder abduction. More typically there is slow but just-perceptible deterioration over 
20-30 years.  
Although FSHD is often regarded as a benign, mild condition (Bell, 1942; Walton and 
Nattrass, 1954, Lunt and Harper, 1991) noted that 19% of heterozygotes will be 
wheelchair-bound by the age of 40 years. This figure increases further with increasing age.  
Life expectancy is typically not compromised. 
 
Instrumental examination. Serum levels of CK in this form of myopathy is increased slightly 
and sometimes normal.  
The EMG shows the signs of a primitive myopathy (polyphasic potentials of low amplitude 
and short duration). The muscle biopsy shows dystrophic changes beyond the features, 
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such as variability in fiber size, necrosis, regeneration and fibrosis, the presence of small 
angulated fibers, as denervation. Initially these were interpreted as a possible sign of 
distress associated with neurogenic muscle, has recently been shown that these small 
fibers contain myosin, suggesting the possibility that it is regenerating fibers. It is also 
frequently the response of moth-eaten. Mononuclear cell infiltrates can be seen in more 
than 30% of biopsies and may erroneously be incurring in the diagnosis of polymyositis 
(Padberg, 1982).  
Recently Reilich et al. (2010) described five patients who carried the pathogenic FSHD 
mutation on chromosome 4q35, whose muscle biopsies revealed numerous rimmed 
vacuoles and filamentous cytoplasmic inclusions in all cases, suggesting to consider FSHD 
in the differential diagnosis of adult-onset distal myopathies with rimmed vacuoles. 
 
1.3 Early-onset FSHD. The infantile form (also known as early-onset FSHD) was first 
described in 1977 by Brooke who described it as a special form of the disorder and even 
suggested a specific clinical course and mode of inheritance.  
In 1994 Brouwer et al. confirmed that despite the wide range of phenotype, FSHD is a 
genetically  homogeneous  disorder,  and  defined  criteria for  the  infantile  form   of  
FSHD as (1) signs or symptoms of facial weakness before the age of 5 years and (2) signs 
or symptoms of shoulder girdle weakness before the age of 10 years. 
In addition to muscle weakness, infantile FSHD may be associated with sensorineural 
hearing loss and retinal vasculopathy. Mental retardation and epilepsy have been reported 
in severe cases (Funakoshi et al 1998; Miura et al 1998; Saito et al, 2007; Trevisan et al, 
2008; Grosso et al, 2011). 
Infantile FSHD is described as a severe and rapidly progressive disease. Its incidence is 
low making up for 4% of the total FSHD population (adults and children) but 58% of the 
FSHD population <18 years (Klinge et al, 2006). In a series of 7 infantile patients followed 
for between 9 and 25 years at the Newcastle Neuromuscular Centre, only two patients had 
a de novo mutation which previously was believed to be the main underlying genetic defect 
in infantile FSHD (Jardine et al, 1994). 
Somatic mosaicism of a parent might have been underrepresented in the previous studies 
of infantile FSHD which date back to the early 1990s. It is now known that almost half of de 
novo FSHD cases arise through a mitotic rearrangement either in the unaffected carrier 
parent of an affected non-mosaic child or in the affected individual (van der Maarel et al, 
2000; Kohler et al, 1996). While a positive family history is rare, patients with infantile 
FSHD may frequently have a parent with somatic mosaicism for the mutation who was 
unlikely to have presented with any symptoms at the time that the child was diagnosed.  
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Whereas the severity and progression in adult FSHD may vary considerably, the variability 
in the infantile form is less marked. The presenting symptom could be usually incomplete 
eye closure during sleep or the inability to smile. Therefore, Möebius syndrome is the main 
differential diagnosis in infants with this presentation. 
In infantile FSHD weakness in the shoulder girdle may be preceded by pelvic girdle 
weakness. There have been no reports on asymmetry of weakness in infantile FSHD. 
Respiratory insufficiency has been reported to be rare in FSHD affecting about 1% of the 
Dutch population (Wohlgemuth et al, 2004). Anyway, spirometry values have to be 
interpreted with care since facial weakness prevents tight mouth closure during the 
assessment and may lead to falsely low results. 
Funakoshi et al. in 1998 examined 140 Japanese FSHD patients from 91 unrelated 
families, of whom twenty patients had small (10-11kb) EcoRI fragments and a high 
frequency of epilepsy (44%) and mental retardation (89%). These authors concluded that 
FSHD patients with a large deletion in the FSHD region tend to have a higher chance of 
clinical phenotypes being associated with central nervous system abnormalities. Miura et 
al. (1998) reported 2 sporadic cases of early-onset scapulohumeral muscular dystrophy 
with mental retardation and epilepsy in unrelated, severely affected females. In both cases, 
Southern blot analysis of the EcoRI-digested genomic DNA, using 2 probes, detected 10-
kb EcoRI fragments, the shortest reported to that time. Patient 1 showed infantile spasms 
at the age of 4 months and localization-related epilepsy at the age of 2.5 years. Muscular 
atrophy in the face, shoulder girdle, and upper arms was observed from the age of 4 years. 
In patient 2, lack of facial expression was noticed since the age of 1 year, and at 4 years 
she was noted to have loss of upward gaze bilaterally. She developed localization-related 
epilepsy at the age of 9 years. From the age of 10 years, weakness of the lower limbs 
progressed and she became wheelchair-bound at the age of 14 years. She had moderate 
sensorineural hearing loss, a loss of upward gaze bilaterally, and tongue atrophy. Their IQs 
were 33 and 45, respectively. They suggested that mental retardation and epilepsy may be 
part of the clinical spectrum of FSHD, especially in very early-onset patients with large 
deletions. 
Up to now data on the life span of infantile patients are also limited but death in infancy or 
early adolescence does not seem to be common.  
Bailey et al. (1986) reported on four patients of one family who all died in adolescence, 
while McGarry et al. (1983) reported one patient with death at the age of five years due to 
respiratory insufficiency caused by recurrent pneumonias. Her creatine-phosphokinase, 
lactate dehydrogenase and aldolase were all elevated four to ten-fold on different 
occasions. There was no family history of any neurological or muscle disorders. 
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1.4 Genetic defect and molecular diagnosis  
 
FSHD is a disease with a unique epigenetic etiology. It is not caused by structural 
mutations within the disease gene as commonly seen in monogenetic traits, but rather 
involves a complex cascade of epigenetic events following contraction of a subtelomeric 
macrosatellite repeat. 
 
Linkage studies. Linkage for FSHD was established in the early 1990s by a genome-wide 
microsatellite scan in a few Dutch families with autosomal dominant FSHD. When 
polymorphic markers became available, it was possible to search for genes responsible for 
or associated with genetic diseases by association analysis and linkage analysis.  
Unfortunately, none of the 35 markers present at that time showed linkage to FSHD 
(Padberg et al, 1984). Next, the search for the FSHD locus was continued by use of 
restriction fragment length polymorphisms (RFLP) (Lunt et al, 1989), but also these 
analyses did not yield any evidence for linkage. By the early nineties, almost 95% of the 
human genome was excluded (Sarfarazi et al, 1989), but the FSHD locus had not been 
found. Then marker technology shifted from RFLPs to (CA)n type microsatellite markers 
(Gelehrter et al, 1998; Litt et al, 1989; Weber et al, 1989). 
One of these markers,  Mfd22 (Weber et al, 1990),  displayed positive  linkage and located 
the putative FSHD locus to chromosome 4 (Wijmenga et al, 1990). 
Subsequently, a number of chromosome 4 markers were tested to identify markers in 
closer  linkage or flanking marker Mfd22. A variable number of a tandem repeat marker 
pH30 (Milner et al, 1989), showed high linkage corresponding to locus D4S139 and located 
the FSHD locus to 4q35 (Wijmenga et al, 1991). Afterward the cosmid 13E, distal to the 
D4S139 locus, was isolated. This clone contained multiple copies of a 3.3 kb repeat 
sequence. An 800 bp probe termed p13E-11 (D4F104S1), proximal to the repeat array, 
was identified. The probe p13E-11 could be used for hybridization of Southern blots of 
human DNA digested with restriction enzyme EcoRI. The use of this probe displayed that, 
in FSHD families, EcoRI fragments, shorter than 28 kb, co-segregated stably with the 
disease through generations (van Deutekom, 1993; Wijmenga et al, 1992a). This probe 
also displayed short EcoRI fragments in sporadic FSHD patients, whereas it was absent in 
the clinically unaffected parents, revealing a de novo DNA rearrangement (Wijmenga et al, 
1992b). Once the rearranged EcoRI fragment had arisen, it could stably be transmitted to 
the next generation in association with the disease (Wijmenga et al, 1992a). Additional 
genetic studies on FSHD families confirmed these findings (Cacurri et al, 1994; Zatz et al, 
1995).  
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In some of the FSHD families without linkage to 4q35, markers on chromosome 12 were 
also tested flanking the regions of two diseases with clinical features similar to FSHD, as 
scapuloperoneal muscular dystrophy and scapuloperoneal muscular atrophy (Tim et al, 
2001). Both disease regions were excluded by extensive linkage analysis (Tim et al, 2001). 
In addition, mutations in the gene myotilin, which has been identified for one of the 
autosomal dominant forms of limb girdle muscle dystrophy, were also eliminated as a 
cause of non-4q linked FSHD (Hauser et al, 2002). 
Further genomic screening has identified a region on chromosome 15 consistent with 
linkage in one non-4q linked FSHD family (Randolph- Anderson et al, 2002). Sequence 
analysis ruled out a possible candidate gene, POLG on 15q25 (Bastress, et al 2004; 
Randolph- Anderson et al, 2002), in which mutations are responsible for progressive 
external ophthalmoplegia (Napoli et al, 2001).  
Other possible candidates in this region were also evaluated (Bastress et al, 2004), but no 
mutations were observed in desmuslin, an intermediate filament protein that may play an 
important role in maintaining muscle integrity (Mizuno et al, 2001; Napoli et al, 2001) nor in 
chromodomain helicase DNA binding protein 2 that may be involved in chromatin structure 
regulation and gene transcription (Napoli et al, 2001; Woodage et al, 1997). The 
sequences of three proteins recently identified to bind D4Z4 (YY1, nucleolin and HMGB2) 
(Gabellini et al, 2002), were also excluded as candidate genes (Bastress et al, 2004). 
In 2007, the apparent absence of the contracted D4Z4 repeat associated with FSHD was 
explained through the finding of a deletion in the region proximal to the D4Z4 repeat array 
that encompasses the p13E-11 (D4F104S1) probe-binding site used in the DNA diagnosis. 
The frequency of such proximally extended deletions has been estimated approximately 
around 3%, but to date, few patients have been described due to the difficulties in the 
molecular identification of such cases (Deak et al., 2007). 
 
D4Z4 units. Not much later the identification of the FSHD polymorphic EcoRI fragments, 
the genetic defect in FSHD was established as a partial deletion of an integral number of 
repeat KpnI fragments, designated D4Z4 (van Deutekom et al, 1993). 
The D4Z4 units are members of a large family of 3.3 kb tandem repeat loci that are located 
on the short arm of the acrocentric chromosomes, the pericentromeric regions (especially 
on chromosome 1), and the telomeric regions of the long arms of chromosomes 4 and 10 
(Hewitt et al, 1994; Lyle et al, 1995).  
The organization of the D4Z4 repeat is rather unusual (Fig. 4), in particular the presence of 
two homeobox sequences within the same open reading frame. Homeobox genes, 
encoding homeodomain transcription factors, often play important roles in embryonic 
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of 10q EcoRI alleles varies between 11 and 300 kb. Moreover, 10% of these alleles are 
shorter than 35 kb (Bakker et al, 1995, 1996), overlapping the 4q alleles, and clearly this 
can complicate the molecular diagnosis of FSHD. However, the presence of a BlnI 
restriction site within the 3.3 kb element associated with chromosome 10q allows the 
discrimination between 4q and 10q alleles (Deidda et al, 1996). As a result, Southern blot 
hybridization of EcoRI and EcoRI/BlnI digested genomic DNA has been used for the 
molecular diagnosis of FSHD (Lunt 1998). Repeat contractions on chromosome 10q are 
nonpathogenic (Lemmers et al, 2001; Zhang et al, 2001).  
Second, apparently unconstrained exchanges between repeat units on both chromosomes 
can be encountered in the population and although generally the precise allele constitution 
for all chromosomes 4 and 10 can be precisely defined, even for the most complicated 
repeat exchanges, it needs sophisticated follow-up experiments often not available in 
diagnostic centres. Repeat exchanges between chromosomes 4 and 10 can be 
encountered in approximately 10% of the population, but despite this dynamic behaviour, 
FSHD is uniquely linked to chromosome 4 and contractions of translocated 4-type repeat 
units on chromosome 10 have never been observed in FSHD (Lemmers et al, 1998; van 
Deutekom et al, 1996a; van Overveld et al, 2000).  
Third, 5−10% of subjects showing FSHD clinical features do not carry D4Z4 deleted alleles. 
Possible explanations for such anomalous cases include a different mutational mechanism 
at 4q35 and the presence of other mutations not linked to the FSHD locus at 4q35. In some 
cases, however, the apparent absence of the pathognomonic short EcoRI fragment was 
due to the presence of a deletion of the region proximal to the D4Z4 repeat array that 
encompasses the p13E−11probe. The frequency of such extended deletions has been 
estimated around 3% (Lemmers et al, 2003). Interestingly in one FSHD family, which was 
previously linked to a chromosomal locus on chromosome 15 (Randolph−Anderson et al, 
2002), the deletion of p13−E11 region was demonstrated (Deak et al, 2007). Further 
studies targeting a cohort of patients failing to exhibit smaller EcoRI/BlnI fragment should 
define the frequency of such deletions in the FSHD population.  
In addition to a contraction of D4Z4, at least one yet to be identified cis-element seems to 
be necessary to develop FSHD. A 4qter polymorphism distal to D4Z4 was recently 
described, giving rise to two distinct 4q chromosome ends: 4qA and 4qB (van Geel et al, 
2002) (Fig. 5).  
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Recently, by analyzing four different polymorphic markers in 86 FSHD patients and 222 
unrelated healthy individuals of European descent, it has been demonstrated that the 
subtelomeric domain of chromosome 4q can be subdivided into nine distinct haplotypes, 
three of which carry the distal 4qA variation (Lemmers et al, 2007). The authors have 
examined the repeat-size variation of D4Z4 and sequence variations in the FSHD locus, 
including a G/C single nucleotide polymorphism (SNP) within the first unit of D4Z4 repeat 
(AF117653:g.6045G→C), the 4qA/4qB polymorphism distal to D4Z4, and a relatively stable 
simple sequence-length polymorphism (SSLP) located 3.5 kb proximal to D4Z4 between 
positions 1532 and 1694 of AF117653. Furthermore, Lemmers and colleagues have shown 
that repeat contractions in two of the nine haplotypes are not associated with FSHD, and in 
particular, in two independent families, they have shown the presence of 4qA-type FSHD 
sized D4Z4 repeats in multiple unaffected relatives, indicating that these alleles are non-
pathogenic. 
These findings suggest that D4Z4 contractions per se are not sufficient to cause disease. 
As a consequence, FSHD might be only associated with D4Z4 contractions as part of 
specific haplotypes and researchers propose that future research should be focused on 
identifying consistent sequence variations for the different haplotypes, since these 
variations may be essential to FSHD pathogenesis. 
Clearly, all those cases of genetically positive, but phenotypically negative patients and 
vice versa shall be carefully studied, since the definition of “protective polymorphisms” has 
important implications for genetic and prognostic counselling. 
Thus further studies are needed to obtain final validation of these prognostic tools. 
 
1.5 Current treatments for FSHD. Currently there is no treatment or cure for FSHD, but 
there are aids that can provide symptomatic relief. FSHD patients have a relatively normal 
life expectancy and therefore sometimes require procedures that will provide prolonged 
relief. 
Many patients with facioscapulohumeral muscular dystrophy eventually have instability of 
the scapula resulting from weakness of the scapula stabilizers. A subset of patients, 
however, has sufficient strength in the supraspinatus and deltoid muscles to flex and 
abduct the arm, if the scapula has been stabilized. Scapulo-thoracic arthrodesis is 
considered a successful treatment method to limit shoulder motion and scapular winging 
caused by FSHD. Bunch et al (1993) fixed the scapula to the ribs in twelve FSHD patients 
and did re-examination from three to twenty-one years after the procedure. Approximately 
50% of the individuals examined by Bunch et al. had preserved deltoid function. All the 
twelve patients obtained solid fusion and all of them experienced a more stable shoulder 
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while they were carrying or lifting objects. All but one patients was capable of forward 
flexion and abduction to 90 degrees or more. These patients had an average of 30 degree 
flexion preoperatively, which increase to 65-125 degrees postoperatively. 
Andrews et al (1998) performed scapula-thoracic arthrodesis in six FSHD patients. The 
raise of flexion and abduction increased. The scapula was clinically and radiologically fused 
to the chest wall in all the patients. Demirhan et al (2009) evaluated the outcomes of 
scapula-thoracic arthrodesis using multifilament cables, performed on 13 patients with 
FSHD (18 shoulders). Solid fusion was obtained in all shoulders and in general active 
abduction range and anterior flexion significatively increased. 
The explosion of molecular genetic information has provided tangible new targets for 
therapeutic interventions in a number of muscular dystrophies, but despite this, no new 
effective therapeutic interventions exist for them. In striving to find effective treatments, 
FSHD offers several advantages, as well as one major disadvantage, over some of the 
other dystrophies. The one disadvantage is that the gene or genes that mediate the effects 
of the deletion remain unknown. Consequently, without knowledge of the pathophysiology 
of FSHD, it’s difficult to devise rational, targeted treatment approaches. 
On the other hand, FSHD has several advantages over other muscular dystrophies when 
considering the conduct of therapeutic trials: 
1. FSHD is a relatively common dystrophy with clearly defined clinical and genetic 
diagnostic criteria making recruitment of patients straightforward. 
2. FSHD has few clinically important extramuscular manifestations that would preclude 
the use of certain pharmaceutical agents 
3. The biggest advantage is the fact that, other than Duchenne, FSHD is the only 
dystrophy whose natural history  has been prospectively studied and in which 
sizable randomized controlled trials have been performed (Personius et al, 1994; 
Tawil et al, 1994; The FSH-DY Group, 1997).    
 
Therapeutic trials in FSHD  
Corticosteroids. Mononuclear inflammatory infiltrates are seen in as many as 40% of 
muscle 
biopsy samples of patients with FSHD (Padberg, 1982). At times this inflammation is 
intense enough to suggest an inflammatory myopathy (Bates et al, 1973). Case reports of 
FSHD patients treated with corticosteroids showed either improvement or no effect (Munsat 
et al, 1972; Bates et al, 1973, Wulff et al, 1982). Some of the patients treated with 
prednisone initially improved in strength (Munsat et al, 1972), though this improvement 
quickly waned and progression resumed (Munsat and Bradley, 1977). The effects of 
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prednisone on FSHD were subsequently studied in a prospective, 3-month, open-label trial 
(Tawil et al, 1997). Prednisone (1,5 mg/kg/day) was administered for 12 weeks to eight 
patients with FSHD. There were no significant changes in measures of muscle strength or 
muscle mass. Given the limited power of the study, no conclusions regarding the effects of 
prednisone in slowing or arresting disease progression could be reached. However, the 
authors concluded that no further trails with prednisone could be justified given the risk 
versus limited benefit of lifelong use of corticosteroids. 
 
Albuterol. Compounds that demonstrate skeletal muscle anabolic properties are logical 
putative therapeutic agents for any muscle-wasting disease. Beta 2 agonists exert a 
number of effects on  muscle metabolism and function including proliferation of satellite 
cells, increased muscle protein synthesis and inhibition of muscle proteolysis (Benson 
1991; Matlin and Delay, 1992; Matlin et al, 1992). A positive 3-month, open-label trial of a 
sustained-release albuterol in FSHD led to the conduct of a 1-year, randomized, placebo-
controlled trial (Kissel et al, 1998 e 2001). In this study 90 FSHD patients were enrolled and 
randomized to receive two different doses of sustained-release albuterol (8mg b.i.d. and 16 
mg b.i.d., twice daily). Although a trend towards improved muscle strength was seen at 3 
months in those groups receiving active drug, no difference between the treatment groups 
was noted at 1 year, even if muscle mass, estimated using dual-energy X-ray 
absorptiometry, was significantly increased at 1 year in the active drug groups in a dose-
dependent fashion. In a subsequent controlled trial of sustained-release albuterol (8 mg 
twice daily) a similar positive effect on muscle mass, measured by computerized 
tomography scan, was noted after 26 weeks, along with a nodest and statistically 
significant improvement in strength in several muscles. (Van der Kooi et al, 2004)  
 
Creatine monohydrate. How creatine-P, which is the immediate source of energy during 
muscle contraction, can improve strength in longstanding dystrophic conditions remains 
unclear. There is evidence that phosphocreatine stores are depleted in some dystrophic  
muscles and that creatine may have cellular protective characteristics (Kemp et al, 1993; 
Pulido et al, 1998). A randomize double-blind, cross-over trial, in a mixed population of 
dystrophies, including 12 FSHD patients, demonstrated slight improvement in overall 
strength following short-term (8-week) supplementation with creatine monohydrate (10.6 
g/day for 10 days followed by 5.3 g/day thereafter) (Walter MC et al, 2000). Given the size 
of the trial and the mixed subjects population, little can be concluded as to the utility of 
creatine supplementation in FSHD. 
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Acid folic and methionine supplementation. The marked hypomethylation of the shortened 
D4Z4 allele or the finding  of the hyopomethylation in both alleles of FSHD patients without 
contraction suggest that hypomethylation plays a critical role in the pathogenesis of FSHD. 
Folic acid and vitamin B12 are essential for the synthesis of methionine, required in the 
maintenance of DNA methylation. Van der Kooi et al (2006) undertook a pilot study to test 
the hypothesis that folic acid and methionine supplementation in FSHD can alter the 
methylation level at D4Z4. No such effect was noted in either FSHD or controls after 12 
weeks of supplementation. 
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Chapter 2 
Clinical protocol and FSHD score 
 
 
FSHD variable onset and unpredictable progression, as well as its high clinical variability, 
even within the same family, and the presence of non-penetrant gene carriers, suggest that 
additional factors can influence the disease outcome. 
As described above, the number of D4Z4 units, in the 4qter region, is considered 
diagnostic for the disease. However, correlation between D4Z4 repeats number and 
disease severity is difficult to establish  and no prognostic tools are available, so far.  
To accurately correlate the molecular defect with the clinical outcome a clinical data 
questionnaire was designed (Lamperti et al, 2010) to evaluate FSHD patients and their 
relatives. The main purpose of the questionnaire is to gather information about the onset 
and evolution of the disease and correlate the disease history with events occurring in the 
patients’ life. 
Several questions have been introduced, based on sporadic observations collected by the 
diverse clinicians.  
A clinical evaluation form was also generated for determining the FSHD clinical score of 
each subject carrying a D4Z4 pathogenic allele. The clinical evaluation scale is divided into 
six independent sections that assess the strength and the functionality of (I) facial muscles 
(scored from 0 to 2); (II) scapular girdle muscles (scored from 0 to 3); (III) upper limb 
muscles (scored from 0 to 2); (IV) distal leg muscles (scored from 0 to 2); (V) pelvic girdle 
muscles (scored from 0 to 5); and (VI) abdominal muscles (scored from 0 to 1). The 
functional examination of six different groups of muscles, integrated with the result of the 
functional quantification of muscle weakness, generates the FSHD clinical score. The total 
score can range from 0, when no signs of muscle weakness are present, to 15, when all 
muscle group tested are severely impaired. The FSHD evaluation scale has been designed 
based on the Brooke et al. (1981) evaluation scale modified by Ricci et al. (1999) and 
Trevisan et al. (2006). The evaluation scale has been specifically adapted for FSHD. 
To assess the reliability of the clinical evaluation protocol the concordance of the FSHD 
score generated by diverse clinicians through the examination of a single patient was 
tested. To this purpose, five meetings were organized. 
Certified neurologists from 11 participating Neuromuscular Institutions were involved. For 
each patient, the functional test was administered by clinician and simultaneously 
evaluated by at least five qualified neurologists (participating at a single meeting) from the 
11 Institutes of the Italian Consortium for FSHD. A functional score was assigned for each 
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muscle group according to the evaluation scale. All tests and evaluations were performed 
in a blind manner with respect to the results of molecular analysis of D4Z4 locus. 
Stati stic analysis demonstrated the robustness of the clinical evaluation protocol that can 
therefore be used by different neurologists in large cooperative clinical studies (Lamperti et 
al, 2010). The relevance of having developed the FSHD score is that such a tool allows for 
translating what is called clinical impression of the progressive involvement of specific 
muscle groups into a number. 
The use of the FSHD score might provide information to define the natural history of the 
disease throughout time. Importantly, the definition of the clinical involvement of specific 
muscle groups by a number will allow the identification and characterization of atypical 
cases. Moreover, the FSHD score can represent a useful way to gauge the efficacy of any 
potential treatment for FSHD (Attachment 1). 
Because of the FSHD variable onset and unpredictable progression, as well as to better 
understand the phenotypical assessment of both the adult and the infantile form of this 
disease, we also designed a clinical data questionnaire about the infantile informations of 
FSHD patients.  
We designed it on the basis on data reported in literature about the early-onset form of 
FSHD. The questions are related to medical conditions or events that could have been 
associated with an infantile onset of the disease, through which we aim to better 
understand the evolution and the prognosis of this form (Attachment 2). 
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Attachment 1. FSHD classic anamnestic records and score 
 
Referring Hospital:     Referring physician: 
Date: 
Patient’s code:      Initials: 
Date of birth:       Sex: □ M □  F 
Family geographical origin: 
Clinical history 
Previous evaluation in other center(s) and which: 
 
Onset 
 
Age: 
Muscle group: 
□  facial muscles   □  pelvic girdle muscles 
□  abdominal muscles  □  lower limb muscles  
 
Asymmetry  □  Yes  □  No 
 
Triggering event (if any) 
 
Associated diseases: 
 
Diabetes 
□  Yes                 □  No  □  Not evaluated       
   □  type 1     □  type 2  Age of onset:   Therapy: 
 
Thyroid Hormones alterations 
□  Yes                 □  No  □  Not evaluated       
   □  hypotiroidism     □  hyperthiroidism    Therapy: 
 
Hepatitis 
□  B                  □  C  □  Toxic        □  Not evaluated 
   Age of onset:   Therapy: 
 
Other disease(s) 
□  Not evaluated              □  Other: 
 
Drugs:  
 
Statins 
□  No                  □  Yes   
   Type:   Dosage:  Duration of the treatment: 
   Modification of the disease:    □  None                □  Worsening  □  Improvement       
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Interferon 
□  No                  □  Yes   
   Dosage:   Duration of the treatment: 
   Modification of the disease:    □  None                 □  Worsening  □  
Improvement       
 
Other treatments (chronic treatments were only considered) 
□  anabolic steroids                  □  creatine   
□  vitamins                   □  estroprogestinic 
□  antitumoral    □  other 
    - molecule:            - molecule: 
 
Pregnancy 
□  No                  □  Yes   Number of pregnancies: 
    Modification of the disease:    □  None                 □  Worsening  □  
Improvement   
 
Spontaneous abortion 
 □  No                  □  Yes   
     Modification of the disease:   □  None                 □  Worsening  □  
Improvement       
 
Menopause 
 □  No                  □  Yes  
     Physiological menopause:    □  Yes                  □  No  Age: 
     Hormonal therapy:   □  Yes                  □  No   
     Modification of the disease:   □  None                 □  Worsening  □  
Improvement    
 
Physical activity 
□  No                  □  Yes  
     Kind of sport:    □  agonistic                  □  not agonistic   
     Modification of the disease:   □  None                 □  Worsening  □  
Improvement    
    
Physiokinesitherapy (PKT) 
□  No                  □  Yes   
     Modification of the disease:   □  None                 □  Worsening  □  
Improvement       
 
Traumatic events 
Surgical operations: 
     Modification of the disease:   □  None                 □  Worsening  □  
Improvement      
     Year: 
Anesthesia: □  General          □  Local  □  Epidural  Molecule:      
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Family history (pedigree): 
 
 
 
 
 
 
 
PART B 
 Functional evaluation: 
 
Face: 
 
 Ability to close eyes: 
 □  normal           □  partial  □  unable to close eyes 
 
 Ability to protrude lips: 
 □  normal           □  partial  □  unable to protrude lips 
 
 Ability to puff out cheeks: 
 □  normal           □  partial  □  unable to puff out cheeks 
 
Scapular girdle: 
 
 Ability to abduct arm: 
 □  whole (180°)           □  complete but abnormal   
□  incomplete but >45°  □  incomplete but <45° 
 
Pelvic girdle: 
 
 Ability to climb 4 stairs: 
 □  without support            
□  without support but abnormally/posterior leg muscle hypotrophy   
□  with support  □  taken more than 12 sec/unable 
 
Ability to walk: 
□  without support           □  with support  □  unable  
 
Ability to stand up from a chair 
□  without support           □  with support  □  unable 
 
Use of wheelchair: 
□  not necessary            □  with manual control   
□  with electric control   □  bed bound 
 
28 Clinical characterization of facio-scapulo-humeral muscular dystrophy (FSHD) with short alleles (<20kb) 
 
Legs: 
  
 Ability to walk on tiptoes and/or heels: 
□  normal     □  on tiptoes only  □  on heels only             □  unable 
 
 
Beevor’s sign: 
 
Beevor’ sign was considered positive if, when the patient was examined in the supie 
position, there was an upward/downward deflection of the umbilicus on neck flexion. 
□  positive            □  negative 
 
PART C 
 
 MRC score: 
Scores range from 0 to 5, with .5 increments (e.g. 3, 3.5, 4, 4.5, etc) 
 
Muscle      Right    Left 
________________________________________________________________________________ 
 Triceps 
 __________________________________________________________________________
 Biceps 
 __________________________________________________________________________ 
 Common finger extensors 
 __________________________________________________________________________ 
 Wrist extensors 
 __________________________________________________________________________ 
 Long fingers flexor 
 __________________________________________________________________________ 
 Wrist flexors 
 __________________________________________________________________________ 
 Quadriceps 
 __________________________________________________________________________ 
 Tibialis anterior 
 __________________________________________________________________________ 
 
 Others: (trophism, lordosis, abdominal muscles, peculiarity, asymmetry) 
 
 
Specific tests: 
 
 Electrocardiogram (ECG): 
 Pulmonary function tests (PFT) (only in wheelchair patients): 
 Creatine phosphokinase (CPK): 
 
Sign: 
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      I – Facial weakness 
 
0 - no weakness 
1 - moderate weakness: 
      partial ability to do at least one of the following tasks: 
- to close eyes 
- to protrude lips 
- to puff out cheeks 
2 - severe weakness 
      unable to do at least one of the following tasks:  
- to close eyes 
- to protrude lips 
- to puff out cheeks 
 
II – Scapular girdle involvement  
 
0 - no involvement 
1 - mild  involvement with no limitation of arm abduction 
2 - arm abduction > 45° 
3 - arm abduction < 45° 
 
III – Upper limbs  involvement*  
 
0 - no involvement 
1 - at least two muscles affected with MRC >3 
2 - at least two muscles with MRC <3 
 
      *the following 4 muscles will be assessed on each side: 1. triceps; 2. biceps; 3. common finger extensor and wrist 
extensors; 4. long finger flexors and wrist flexors. 
Only the weaker muscles will be considered for evaluation. 
 
IV – Legs  involvement 
 
The ability to walk on tiptoes and heels will be assessed on each side:  
 
0 - no involvement 
1 - unable to walk on tiptoes or heels (only one task impaired) 
2 - unable to walk on tiptoes and heels (two tasks impaired) 
 
V – Pelvic girdle  involvement  
 
0 - no involvement 
1 - able to walk and to climb stairs without support but abnormally/because of posterior leg muscle        
hypotrophy 
2 - able to walk unaided, to climb stairs or to stand up from a chair with support 
3 - able to walk unaided but unable to stand up from a chair or to climb stairs without support/more than    12 
seconds 
4 - able to walk with support 
5 - wheelchair bound 
 
VI – Abdominal muscle  involvement  
 
0 - no involvement 
1 - presence of Beevor’s sign 
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Attachment 2. FSHD infantile anamnestic records 
 
Referring Hospital:     Referring physician: 
Date: 
Patient’s code:      Initials: 
Date of birth:       Sex: □ M □  F 
Family geographical origin: 
Pregnancy 
Active fetal movements  □  Yes   □  Reduced  □  Normal 
  
          □  No 
Fetal cardiac beats  □  Normal  □  Altered 
Placental dysfunction  □  Yes   □  No   weight: 
Diseases/infections  □  Yes                 □  No 
Ultrasound   □  Yes        □  No 
Routine ultrasound          □  Normal  □  Altered 
Morphological ultrasound        □  Normal  □  Altered 
Therapy during pregnancy  □  Yes   Drugs: 
    □  No 
Birth 
Partum    □  Eutocic  □  Dystocic   week: 
Fetal position   □ Normal  □  Podalic 
Weight    Lenght    Apgar 
Revived   □  Yes       □  No 
Cianosis   □  Yes   □  No 
Mechanical ventilation □  Yes   □  No  
Clubfoot   □  Yes   □  No 
Neonatal jaundice  □  Yes   □  No 
Perinatal period/ months after 
Breastfeeding     □  Yes   □  No 
Breast Suction     □  Vigorous               □  Normal             □  
Reduced 
Facial nerve palsy’s diagnosis  □  Yes               □  No 
Moebius syndrome’s diagnosis  □  Yes   □  No 
Hip dysplasia     □  Yes         □  No 
Upper limbs     □  Normal            □  Altered 
Facial hypomimia    □  Yes       □ No 
Floppy      □  Yes       □  No 
 
Psychomotor development 
Sitting alone: age  (months) 
Self-standing: age   (months) 
Walk alone:  age   (months) 
Social smile    □ Yes  age   (months)  □  No 
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Familiarity 
□  Yes  □  No □ Maternal line □  Paternal line □  Brothers/sisters 
Data collection 
Mechanical ventilation   □  Yes  (age:          )  □  No 
Vision problems    □  Yes  (age:          )  □  No 
Hypoacusia     □  Yes    □  No 
Academic success    □  Yes    □  No 
Cognitive impairment    □  Yes    □  No 
Loss of walking     □  Yes (age:           )  □  No 
First year of life 
Neurological examination  
Hypotonia      □  Yes            □ No    
Facial mimicry     □  Normal               □  Absent 
Antigravity limb movements   □  Possible          □  Impossible 
Hospital admission    □  Yes            □  No 
      Clinical report: 
After the first year of life 
Neurological examination  
See FSHD clinical form 
Lagophtalmos    □  Yes            □  No 
Gowers     □  Yes            □  No 
Waddling gate    □  Yes            □  No 
Steppage    □  Yes            □  No 
Scapular winging   □  Yes            □  No 
Instrumental tests 
Blood tests   CK  UI/L 
Electrophysiological tests EMG/ENG  □  Yes   Results: 
  
□  No 
    BAERs  □  Yes   Results:   
□  No 
    EEG    □  Yes   Results: 
  
□  No 
Neuroradiological tests Cerebral MRI    □  Yes   Results: 
  
□  No 
    Muscular MRI   □  Yes   Results:  
□  No 
Eye examination  Fundus oculi  □  Yes   Results: 
  
□  No 
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ERG   □  Yes   Results: 
  
□  No    
Fluorescein angiography  □  Yes  Results: 
  
□  No 
 
Ear examination  Audiometry       □  Yes             Results:  
 
      □  No  
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Chapter 3 
Reasearch aim 
 
A patient usually recognizes the disease in his teens but an extreme variation in onset is 
reported, ranging from early infancy to late fifties, even within 
families with all affected members carrying the same genetic 
lesion. 
While much is known about the clinical course of adult FSHD, 
data on  the ‘‘infantile phenotype’’ and especially on the 
progression of the disease in early-onset patients are limited.  
The evaluation of the size of the D4Z4 alleles is the diagnostic 
test for FSHD. As shown in Figure 6, the presence of alleles 
EcoRI less than 38 Kb is considered diagnostic for the disease. 
A correlation between the length of the EcoRI fragment and the 
clinical course was evaluated in several studies and was shown 
that the more severe phenotype is associated with smaller D4Z4 
alleles (Zatz et al, 1995, Lunt et al, 1995;  Tawil et al, 1996, Ricci 
et al, 1999). 
Studies extended to a larger group of patients showed that the n
critical determinant of the age of onset and disease severity. Ind
alleles containing from 1 to 3 D4Z4 units are associated with a s
those containing from 4 to 7 units are found in the most common fo
alleles containing from 8 to 10 D4Z4 units are found in the most a
with reduced penetrance (Zatz et al, 1995, Lunt et al, 1995; Tawil 
1999). 
The aim of this research is to characterize, in our cohort of FSHD pa
fragment (allele <20 kb), phenotypical features to better understand
to add data on the progression and to acquire useful informations 
prognosis of the early-onset form of FSHD. 
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umber of repeats is a 
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evere form of disease, 
rm of the disease and 
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 the clinical variability, 
for both diagnosis and 
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Chapter 4 
Materials and Methods 
 
4.1 Clinical assessment. Our cohort of patients with a molecular diagnosis of FSHD 
included 35 consecutive index cases with a size of allele D4Z4 <20 kb.  
All patients were evaluated according to the two clinical above mentioned questionnaires, 
focusing on first clinical disturbances manifested by the patient, age of onset and 
associated-diseases. To avoid potential patient bias, the patient or relatives answered the 
questionnaire with the assistance of the clinician. Either the patient’s own recollection of 
initial symptoms or the first clinical abnormality observed by relatives, as in the case of 
children, were considered significant.  
The clinical severity of FSHD has been numerically defined as assessed by the FSHD 
score, obtained by the FSHD clinical form (described above). 
 
4.2 Molecular diagnosis. Molecular analysis was carried out at the laboratory in Modena 
(MIOGEN-Lab), which provides FSHD molecular diagnosis for the Italian National Health 
System.  
The extraction method involves, at first, the isolation of leukocytes from peripheral blood 
and their inclusion in agarose; then, the canonical procedures for the purification of DNA 
are performed, so that it is protected from the agarose to the electrophoresis process. The 
DNA is analyzed by means of digestion with specific restriction enzymes, in particular, with 
EcoRI and BlnI. The restriction fragments obtained is separated according to their 
molecular weight, by pulsed-field electrophoresis (PFGE) on 1% agarose gel. The DNA, 
after the electrophoresis, is transferred from the gel to a nylon membrane by the technique 
of Southern blotting. The membrane is hybridized with a specific probe radioactively 
marked with αP32 and, after appropriate washing, subjected to autoradiography. The probe 
used in molecular diagnostic test is called p13E-11 and recognizes a sequence proximal to 
the sequence of units D4Z4 repeat (locus D4F104S1). The size of restriction fragments 
viewed in this way are evaluated by comparing the bands of a molecular weight marker. 
The molecular weight of each fragment corresponds to a defined number of D4Z4 repeat 
units. To quantify the end of the molecular weight of less than 4q alleles of 50 kb, the 
genomic DNA purified by standard methods of DNA extraction with phenol-chloroform must 
be analysed. The DNA digested with enzymes EcoRI and BlnI restriction, is subjected to 
agarose gel electrophoresis to the linear concentration of 0.4% and hybridized with the 
probe p13E-11. 
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4.3 Statystical analysis. All the continuous variables were summarised by means and 
standard deviations (i.e. age of onset, age at evaluation, age of walking loss). Both discrete 
and dichotomous variables were expressed by frequencies (i.e. gender, associated-
diseases). The continuous variables were tested for their normal distribution according to 
the Kolmogorov-Smirnov test. A p value <0.05 was considered significant to reject the null 
hypothesis that the considered variable is not normal. Non-parametric correlations (i.e. 
Spearman’s correlation coefficient) were used to investigate any possible association 
between demographic, genetic and clinical characteristics of the patients enrolled. 
SIGMAPLOT ver. 11.0  (Sigmaplot Software Inc, USA) was used for the statistical analysis. 
A p value <0.050 was considered statistically significant. 
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Chapter 5 
Results 
 
5.1 Clinical features. Genetic and epidemiological characteristics of the index patients are 
listed in table 1. 
 
Table 1. 
 
Patient n. Sex Case Fragment size Age of onset 
(years) 
Age at evaluation 
(years) 
1 F de novo 14 2 20 
2 F de novo 14 12 24 
3 M de novo 14 0 17 
4 F de novo 14 4 14 
5 M Spor 17 27 60 
6 M de novo 17 12 38 
7 M de novo  16 13 14 
8 M Spor 17 5 44 
9 M de novo 19 10 25 
10 M Spor 17 32 32 
11 F Fam 16 25 27 
12 M de novo 12 10 29 
13 M Fam 17 16 31 
14 M de novo 14 2 6 
15 F de novo 11 16 23 
16 F Fam 17 15 16 
17 F de novo 19 20 47 
18 F Fam 16 7 36 
19 F Spor 17 27 32 
20 M de novo 11 7 10 
21 M de novo 12 1 7 
22 M de novo 11 5 33 
23 F Spor 12 6 50 
24 F Fam 16 4 50 
25 M de novo 17 2 10 
26 M Fam 16 3 22 
27 M Fam 16 13 35 
28 M Spor 14 12 41 
29 F Spor 12 27 41 
30 F Spor 12 11 27 
31 F de novo 17 11 28 
32 F Fam 14 3 12 
33 F de novo 15 8 27 
34 F Spor 14 2 42 
35 M de novo 12 2 22 
 
 
Eighteen males and 17 females were enrolled. Mean age at evaluation was 28,3 +13,3 
years (range 6-60 years), while the mean age at onset was 10,6 + 8,6 years (range 0-32 
years). Interestingly, during the anamnestic data collection, in 16 out of the 35 patients 
(45,7%) signs of muscular weakness were already present before the declared age of 
onset. The predominant sign of weakness in these cases was a deficit in eye closure, 
which became most apparent during sleep, as well as during blowing on candles. 
Eighteen patients (51,4%) had a de novo mutations, 9 (25,7%%) were sporadic (no 
molecular data concerning family were available) and 8 (22,9%) were familial cases. 
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5.2 Distribution of muscle weakness and progression. Clinical characteristics are 
shown in table 2.  
 
Table 2. 
 
Patient n. Localization at onset Asymmetry at onset Score Clinical involvement 
1  Facial No 6  
2 Scapular Yes 13 Clubfoot  
Breatsfeeding problems 
3 Facial No 12  
4 Scapular  No 15 Breastfeeding problems 
Hip dysplasia 
Wheelchaired 
5 Facial No 13  
6 Scapular Yes 7 Breastfeeding problems 
7 Scapular No 3  
8 Scapular Yes 14  
9 Legs Yes 8  
10 Facial No 2  
11 Legs No 8  
12 Scapular Yes 13 Retinopathy 
13 Facial No 2  
14 Facial No 8  
15 Scapular No 3 Clubfoot 
16 Scapular No 5  
17 Legs No 9  
18 Facial Yes 14 Mental retardation 
Severe dysphagia 
Mechanical ventilation 
Wheelchaired 
19 Scapular Yes 3  
20 Scapular No 7  
21 Scapular No 2 Hypoacusia 
22 Scapular No 12 Breastfeeding problems 
Mental retardation 
Epilepsy 
Mechanical ventilation 
Wheelchaired 
23 Scapular Yes 9 Breastfeeding problems 
Hypoacusia 
24 Facial No 12  
25 Facial No 8 Clubfoot 
Mental retardation 
Epilepsy 
26 Facia Yes 12  
27 Scapular Yes 11  
28 Scapular No 15 Wheelchaired 
29 Scapular No 9  
30 Facial Yes 14 Retinopathy 
Hypoacusia 
Wheelchaired 
31 Facial Yes 12  
32 Facial No 13 Hypoacusia 
Wheelchaired 
33 Facial No 13 Hypoacusia 
Wheelchaired 
34 Facial Yes 13 Hypoacusia 
Wheelchaired 
35 Facial no 13 Hypoacusia 
Mental retardation 
Wheelchaired 
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Thirteen patients (37,1%) showed asymmetric symptoms at onset, which were represented 
by:  
- facial weakness 16/35 patients (45,7%) 
- scapular winging or weakness during shoulder abduction 16/35 patients (45,7%) 
- legs’ weakness with abnormal gait 3/35 patients (8,6%) 
No patients had abdominal involvement at onset. 
To better evaluate the FSHD score, we divided our patients in four groups: the first one 
(score: between 0 and 1) consisted of patients with no significant functional deficits in any 
muscle group; the second group (score between 2 and 4) was made of patients with a 
slight involvement in one or more muscles among the facial district, shoulder girdle, upper 
limbs or abdominal muscles; patients whose score was between 5 and 10 showed a limited 
ability to raise their arms, walking on toes and/or heels;  patients with a score > 10 had a 
general weakness in all muscle groups, associated with partial or total inability to walk. No 
patients had a score between 0 and 1; 6/35 (17,1%) had a score between 2 and 4; 11/35 
patients (31,4%) showed a moderate severity of disease with a score between 5 and 10. 
Eighteen patients (51,4%) had a score >10, with a very severe phenotype.  
A total of 9/35 patients (25,7%) became wheelchair-dependent at a mean age of 23,7 + 8,7 
years (range 9-37). The duration between the onset of first symptoms and the wheelchair 
use was 16,7+7,4 years (range 5-25).  
Only two patient (5,7%) needed mechanical ventilation for a very severe restrictive lung 
disease (one of these patients showed also a severe dysphagia). 
 
5.3 Additional findings. Four patients had problems during their mothers’ pregnancy. In 
two cases there were placentar dysfunction, in the other two cases there were associated-
diseases during pregnancy (i.e. gestosis in the last month of pregnancy and Herpes 
Symplex infection in the first trimester of pregnancy). 
Eight/35 patients (22.9%) had problems during childbirth, as cyanosis and neonatal 
jaundice.  
One patient (2.9%) showed hip dysplasia, while 3 patients (8.6%) had clubfoot that 
required orthopaedic treatments. 
In two patients (5.7%) a retinopathy was diagnosed in childhood or adolescence; two 
patients (5.7%)  had some tortuous retinal vessels but not true teleangectasia by 
fundoscopy.  
Seven patients (20%) had a diagnosis of sensorineural hearing loss, needing in one case 
hearing aids. Four patients (11,4%) had mental retardation and 2 (5.7%) were epileptic.  
Results are shown in Table 3. 
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Table 3. Results. 
N. patients 35 % 
M/F 18/17 51,4/48,6 
De novo 
Spor 
Famil 
18 
9 
8 
51,4 
25,7 
22,9 
Onset (years) 
<10 
tra 10 e 15 
>15 
 
19 
8 
8 
 
54,3 
22,9 
22,9 
Ancillary signs 16 45,7 
Asimmetry at onset 13 37,1 
Localization 
Facial 
Scapular 
Abdominal 
Legs 
 
16 
16 
0 
3 
 
45,7 
45,7 
0,0 
8,6 
Score 
between 0 and 1 
between 2 and 4 
between 5 and 10 
>10 
 
0 
6 
11 
18 
 
0,0 
17,1 
31,4 
51,4 
Problems during pregnancy 4 11,4 
Problems during partum 8 22,9 
Clubfoot 3 8,6 
Hip dysplasia 1 2,9 
Breastfeeding problems 5 14,3 
Dysphagia 1 2,9 
Mechanical ventilation 2 5,7 
Retinopathy 2 5,7 
Cognitive impairment 4 11,4 
Hypoacusia 7 20,0 
Epilepsy 2 5,7 
Loss of walking 9 25,7 
 
 
In order to understand if the numbers of D4Z4 alleles can influence either the onset or the 
severity of disease, we made a correlation between the allele size and both the 
epidemiological and clinical manifestations in our population. Statystical analysis showed a 
positive correlation between the allele dimension and the age of onset (p=0,032), the 
childbirth’s problems (p= 0,013), loss of walking (p=0.037) and the hypoacusia (p= 0,018). 
No correlations were found between allele size and the other clinical signs. The age of 
onset correlated with hypoacusia (p=0.023) only. Even though 18/35 patients (51,4%%) 
had a FSHD score >10, there was no correlation with the number of D4Z4 units. 
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No correlation between the value of score and genetic data were found, neither with the 
age of onset of disease, but a correlation between the score and the presence of early 
signs of muscular weakness was detected (p=0,004).  
Statistical analysis’ results are shown in table 4, 5 and 6. 
 
Table 4. Correlation between the allele and epidemiological, genetic and clinical characteristics. 
 
     Rho    p 
 
Sex     -0,075    0,666  
Case      
  de novo    0,205    0,235 
  spor   -0,003    0,984 
  fam   -0,241    0,162 
Age of onset     0,362    0,032 
Score     -0,189    0,274 
Previous signs of weakness    0,069    0,690 
Pregnancy     0,195    0,260 
Childbirth      0,416    0,013 
Clubfoot       0,097    0,573 
Hip dysplasia     0,078    0,654 
Retinopathy     0,286    0,095 
Cognitive impairment    0,118    0,497 
Hypoacusia      0,397    0,018  
Epilepsy      0,062    0,721  
Loss of walking     0,353    0,037 
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Table 5. Correlation between the age of onset and epidemiological, genetic and clinical characteristics. 
 
      Rho    p 
Sex      0,150    0,386  
Case      
  de novo    0,329    0,053 
  spor   -0,305    0,074 
  fam   -0,074    0,670 
Allele      0,362    0,032 
Score     -0,270    0,116   
  
Previous signs of weakness    0,082    0,635 
Pregnancy    -0,187    0,280 
Childbirth      0,179    0,301 
Clubfoot      -0,025    0,884 
Hip dysplasia     0,128    0,462 
Retinopathy    -0,036    0,833 
Cognitive impairment    0,303    0,076 
Hypoacusia     0,383    0,023 
Epilepsy      0,226    0,190  
Loss of walking     0,289    0,091 
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Table 6. Correlation between the score and epidemiological, genetic and clinical characteristics. 
 
      Rho    p 
Sex      0,160    0,357  
Case      
  de novo    0,148    0,393 
  spor   -0,192    0,266 
  fam    0,023    0,891 
Allele     -0,189    0,274   
  
Age of onset    -0,270    0,116   
  
Previous signs of weakness   -0,466    0,004 
Pregnancy    -0,062    0,718   
  
Childbirth      0,105    0,545   
  
Clubfoot       0,096    0,578 
Hip dysplasia    -0,282    0,099 
Retinopathy    -0,282    0,099 
Cognitive impairment   -0,184    0,288 
Hypoacusia    -0,228    0,186 
Epilepsy      0,030    0,859  
Loss of walking    -0,652    <0,001 
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Chapter 6 
Discussion and conclusion 
 
FSHD clinical symptoms may appear in adult ages in most of the cases, but they may 
appear in early childhood, as well.  
In our study, we reported the genetic and clinical data of a population of FSHD patients 
with the dimension of the allele <20 kb. 
 
Onset and progression. In most of the cases patients become symptomatic in their 
adolescence, when the individual notices symptoms that reveal shoulder girdle weakness 
or signs of muscle wasting in this region (Jardine et al, 1994; Lunt et al, 1991; 
Padberg,1982; Zatz et al, 1998; Orrell, 1999). However, the true age of onset of the 
disease may appear several years earlier than indicated by patients complaining. In our 
population the mean declared age at onset was 10,6 years (range 0-32 years), but 
interestingly during the anamnestic data collection, 16 out of the 35 patients (45,7%)  
showed signs of muscular weakness before the declared age of onset, being represented 
in most of them by a deficit in eye closure mainly during sleep or by the inability to puff out 
cheeks. It represents an interesting observation because it allows us to say that the 
prevalence of early-onset form of FSHD may be underestimated. 
We found a positive correlation between the age of onset and the dimension of the allele, 
confirming that, as previously reported, smaller EcoRI fragments are associated to an 
early-onset of the disease. There was no correlation between the age of onset and the 
score in our population, but we found that the presence of not-recognized early signs of 
muscular weakness correlates with the score. Eighteen patients (51,4%) had a score >10, 
with a very severe phenotype. Although the number of patients is small and this result 
needs to be confirmed in a larger sample, this observation further confirms that the early-
onset FSHD is a progressive disease and has a more severe evolution, in accordance with 
other studies (Zazt et al, 1995; Lunt et al, 1995; Tawil  et al, 1996; Goto et al, 1995).  
51,4% of our patients were de novo mutations and eight of these (22,9%) had the more 
severe score (>10). Several controversial observations about the role of new mutation in 
the early-onset FSHD were published, but recently has been reported that in a series of 7 
infantile patients followed for between 9 and 25 years at the Newcastle Neuromuscular 
Centre, only two patients had a de novo mutation which previously was believed to be the 
main underlying genetic defect in infantile FSHD (Jardine, 1994). Even though in our 
population no correlations were found between the disease age of onset, evolution and 
cases, this finding needs to be confirmed in a larger number of patients.  
44 Clinical characterization of facio-scapulo-humeral muscular dystrophy (FSHD) with short alleles (<20kb) 
 
In our population the 25,7% of patients became wheelchair-dependent at a mean age of 
23,7 + 8,7 years (range 9-37). Seven/9 had an age of onset <10 years, while 2/9 had an 
age of onset respectively of 12 and 11 years (patient number 28 and number 30, 
respectively), but presented early signs of muscular weakness. Interestingly, the allele size 
correlated with loss of walking, showing how the early-onset form of FSHD has a more 
severe progression. In about half of the adult patients weakness is known to gradually 
descend in a characteristic fashion beginning in the face and slowly progressing to the 
shoulder and upper-arm musculature and then to the abdominal and foot extensors 
muscles. In contrast, in infantile FSHD weakness in the shoulder girdle may be preceded 
by pelvic girdle weakness (Klinge et al, 2006). Just 3 of our patients showed a pelvic and 
legs’ involvement at onset. None of the patients who became wheelchaired-dependent 
presented legs or pelvic girdle involvement at onset. As leg weakness is easier to detect in 
young children than facial or shoulder  girdle weakness, several parents gave a definite 
history of onset of legs involvement and maybe the precise sequence of involvement is 
unclear.  
Progressive respiratory failure during childhood or in young adults is rare in patients with 
FSHD, affecting about 1% of the Dutch population (Wohlgemuth et al, 2004). McGarry et al 
reported a 5-year-old girl with early-onset FSHD who died of progressive weakness and 
recurrent pneumonia (McGarry et al, 1983). Yasukohchi et al (1988) reported a 13-year-old 
FSHD boy with progressive severe restrictive-type respiratory failure and cor pulmonale, 
leading to death. Nakagawa et al (1997) described 3 early-onset FSHD cases and artificial 
ventilator support after tracheotomy in 2 cases (respectively at the age of 22 and 41).  
Only two of our patients (5,7%) need mechanical ventilation for a very severe restrictive 
lung disease. Our data confirm that respiratory failure is a rare complication of FSHD, but 
requires mechanical support to prevent death. 
 
Associated-disorders. Extramuscular manifestations in FSHD represent a controversial 
clinical issue. 
Some studies reported that auditory impairment was present in most FSHD patients but not 
significantly found to be associated with FSHD by subsequent studies (Rogers MT et al, 
2002; Trevisan et al, 2008a). Recent reports pointed out that it tends to occur in those 
patients carrying a very short allele  (Trevisan et al, 2008b).  Seven of our patients (20,0%) 
had hypoacusia, needing in one case hearing aids. We found a correlation between 
hearing impairment and the dimension of EcoRI fragments (p=0,013), confirming that, as 
reported in literature, hearing loss tends to occur more frequently in patients with large 
4q35 deletions. All but one of our patients who had hearing impairment had an onset 
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before the age of 10 years. The remaining patient had an onset at age 11, but showed 
clinical signs previously. Furthermore, the correlation between hypoacusia and the age of 
onset we found confirms that the hearing loss is more common in early-onset FSHD. 
The term Coats’ disease is generally used to describe a sporadic unilateral retinovascular 
disease. Shields et al. (2007) noted that retinal telangiectasia compatible with Coats’ 
disease can be an extramuscular manifestation of FSHD but that most affected patients 
have asymptomatic retinal telangiectasia found at ocular screening after diagnosis of 
FSHD. They described a young child who had advanced eye findings of unilateral 
neovascular glaucoma from bilateral retinal telangiectasia 3 years before FSHD became 
apparent. Coats’ retinopathy has been reported in those FSHD patients with the earliest 
onset and most severe evolution (Small, 1968; Matsuzaka et al, 1986; Miura et al,1998). 
Only 2 of our patients had a retinopathy: one patient had a diagnosis of Coats’ disease 
since the age of 5 years, while the other had a diagnosis of generic retinopathy since the 
age of 17 years. Two other patients had some tortuous retinal vessels but not true 
teleangectasia by fundoscopy. Although uncommon, since retinal vasculopathy with 
capillary teleangiectasia is known to be associated with FSHD, every FSHD patients, 
especially with visual deterioration, should underwent a careful eye examination. 
The involvement of central nervous system in FSHD is reported in those patients carrying 
larger gene deletions. Epilepsy may be observed in the context of muscular dystrophies 
and it may include both generalized and focal seizures. In Fukuyama congenital muscular 
dystrophy, epilepsy may be related to brain malformations occurring in this disorder, while 
in Duchenne or Becker muscular dystrophy, limb-girdle muscular dystrophy type 2A or 
calpainopathy, the pathogenetic mechanism of epilepsy remains unclear as patients 
commonly have normal brain MRI. The frequency of mental retardation in FSHD patients is 
estimated to be less than 2% (Funakoshi et al, 1998). Epilepsy with partial seizures was 
found in 2 of our patients and in both was associated to mild mental retardation. Other two 
of our patients had an isolated mental retardation. In all of these cases cerebral MRI was 
not performed. In literature, the reported cases of epilepsy or mental retardation were 
confined to a subset of early-onset group with a very small EcoRI fragments (10-11 kb) 
(Funakoshi et al, 1998). It was hypothesize that the 4q35 deletion induces a central 
nervous system defect, but only in cases with largest deletions (Bindoff et al, 2006). In 
particular, the observation that patients with a very short allele are more frequently affected 
by central nervous system defects, led to the hypothesis that large deletions may 
determine greater position effect variegation on genes within close proximity. We didn’t find 
any correlation between the allele sizes and these associated-diseases and all our patients 
had a greater allele dimension (from 12 to 17 kb). Our data, in association with others 
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reported in literature, led us to consider the possibility that epilepsy and mental retardation 
are a further clinical expression of the central nervous system involvement in FSHD even in 
those patients with greater 4q35 fragments. 
In conclusion, the early-onset FSHD patients show a more severe progression than the 
patients with classic form but variable phenotypes. We provide further evidences that 
extramuscular manifestations may occur in this form, but a close correlation between 4q35 
fragments size and clinical severity is not constant. A more accurate anamnestic data 
collection and a more extensive instrumental screening are required to identify cases with 
early-onset and improve their management. 
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